Skip to content

Asset turnover at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
0.7×
PTC Therapeutics logo
PTC TherapeuticsPTCT
0.3×-0.5×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
0.0×
Vericel logo
VericelVCEL
0.6×0.0×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
0.1×+0.1×

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$1.71B+303%
Enterprise value$1.62B+308%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Calculated from Capricor Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Capricor Therapeutics's asset turnover?
Capricor Therapeutics (CAPR) reported asset turnover of 0× in Q4 2025.
How has Capricor Therapeutics's asset turnover changed year-over-year?
Capricor Therapeutics's asset turnover decreased by 100.0% year-over-year, from 0.2× to 0×.
What is the long-term trend for Capricor Therapeutics's asset turnover?
Over 3 years (2020 to 2025), Capricor Therapeutics's asset turnover has grown at a -100.0% compound annual growth rate (CAGR), from 0× to 0×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.